Perrigo gets tentative FDA nod for colon cleanser
Branded HalfLytely has annual US sales of $80 million.
Brand HalfLytely, made by Braintree Laboratories Inc. has annual US sales of $80 million, according to Wolters Kluwer.
Novel Laboratories will manufacture the product exclusively for Perrigo, which expects to launch the kit containing the tablet and powder when the patents expire on September 25. Since Novel Laboratories was the first company to apply for an Abbreviated New Drug Application (ANDA) with the FDA, Perrigo will have 180 days marketing exclusivity.
Perrigo's share closed at $57.49 on Nasdaq yesterday, and was unchanged in early trading on the TASE today at NIS 219.60.
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options